使用减重药后体重下降为何不明显？人工智能试图筛出“超级应答者”

Core Viewpoint - The article discusses the increasing confusion among doctors and patients regarding the selection of GLP-1 weight loss medications, highlighting the lack of clear recommendations and the variability in patient responses to these drugs [2][3]. Group 1: Current Market Overview - Three GLP-1 weight loss drugs are currently available in China: Eli Lilly's Tirzepatide, Novo Nordisk's Semaglutide (Nuoheying), and Innovent Biologics' Ma Shidu [2]. - The effectiveness of these weight loss medications varies among individuals, with no definitive recommendation standards established by healthcare professionals [2]. Group 2: Patient Response Analysis - A study analyzing over 135,000 patients found that approximately 12.5% are "super responders," losing over 15% of their body weight within a year, while 35% are "moderate responders" (5% to 15% weight loss), and 47% are "mild responders" (less than 5% weight loss) [2][3]. - Among patients using Tirzepatide, 23%-28% experienced less than 5% weight loss, while for Semaglutide, this figure ranged from 30%-43% [3]. Group 3: Personalized Treatment Approaches - Researchers are exploring new methods to identify more "super responders" using large-scale data analysis and artificial intelligence to match patients with the most effective GLP-1 medications based on their clinical characteristics [3][4]. - For instance, patients with muscle stiffness but no knee pain or osteoarthritis are more likely to respond well to Tirzepatide, indicating the importance of individual health conditions in treatment efficacy [3]. Group 4: Future Directions - The next goal for researchers is to develop an algorithm that provides scoring to indicate the potential benefits and risks of each weight loss drug under various conditions, which will be validated in prospective studies [4].